The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention
Open accessAbstract
BACKGROUND: The Breast Cancer Prevention Trial demonstrated that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer among women at elevated risk for the disease. The U.S. Food and Drug Administration (FDA) subsequently approved tamoxifen for women aged 35 years or older with a 5-year breast cancer risk of 1.67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio. METHODS: We used weighted data from the year 2000 National Health Interview Survey Cancer Control Module to estimate the total number of U.S. women, aged 35-79 years, who were eligible for tamoxifen chemoprevention based on the FDA eligibility criteria. We also estimated the numbers of white and black women who would benefit from tamoxifen chemoprevention on the basis of a positive benefit/risk index developed by Gail et al. RESULTS: Of the 65,826,074 women aged 35-79 years without reported breast cancer in the United States in 2000, 10,232 816 women (15.5%, 95% confidence interval [CI] = 14.7% to 16.3%) would be eligible for tamoxifen chemoprevention. The percentage of U.S. women who would be eligible varied dramatically by race, with 18.7% (95% CI = 17.8% to 19.7%) of white women, 5.7% (95% CI = 4.3% to 7.5%) of black women, and 2.9% (95% CI = 2.1% to 3.9%) of Hispanic women being eligible. Of the 50,104,829 white U.S. women aged 35-79 years, 2,431,911 (4.9%, 95% CI = 4.3% to 5.4%) would have a positive benefit/risk index for tamoxifen chemoprevention. Of the 7,481,779 black U.S. women aged 35-79 years, only 42,768 (0.6%, 95% CI = 0.2% to 1.3%) would have a positive benefit/risk index. Among white women, 28,492 (95% CI = 24,693 to 32,292) breast cancers would be prevented or deferred if those women who have a positive net benefit index took tamoxifen over the next 5 years. CONCLUSION: A substantial percentage of U.S. women would be eligible for tamoxifen chemoprevention according to FDA criteria, but a much smaller percentage would have an estimated net benefit. Nevertheless, this latter percentage corresponds to more than two million women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., & Mulvihill, J. J. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1879 · Cited by 3,334
Self-citation(2001) · Technometrics · doi:10.1198/tech.2001.s612 · Cited by 989
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Veronesi, U. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04394-3 · Cited by 804
Design and estimation for the National Health Interview Survey, 1995-2004
Botman, S., & Moriarity, C. L. (2000) · Cited by 785
Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer Incidence
Costantino, J. P., Gail, M. H., Pee, D., Anderson, S., Redmond, C. K., Benichou, J., & Wieand, H. S. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1541 · Cited by 765
Self-citation(2002) · The Lancet · doi:10.1016/s0140-6736(02)09962-2 · Cited by 747
Weighing the Risks and Benefits of Tamoxifen Treatment for Preventing Breast Cancer
Gail, M. H., Costantino, J. P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., & Vogel, V. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1829 · Cited by 670
Self-citation
Cited by
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji372 · Cited by 1,339
The tumour microenvironment as a target for chemoprevention
Albini, A., & Sporn, M. B. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2067 · Cited by 823
Tice, J. A., Cummings, S. R., Smith-Bindman, R., Ichikawa, L., Barlow, W. E., & Kerlikowske, K. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00004 · Cited by 537
Visvanathan, K., Hurley, P., Bantug, E., Brown, P., Col, N. F., Cuzick, J., Davidson, N. E., DeCensi, A., Fabian, C., Ford, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.3122 · Cited by 307
Priorities for the primary prevention of breast cancer
Colditz, G. A., & Bohlke, K. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21225 · Cited by 277
Metadata
- Authors
- Freedman, A. N., Graubard, B. I., Rao, S. R., McCaskill-Stevens, W., Ballard-Barbash, R., & Gail, M. H.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-02
- Volume
- 95
- Issue
- 7
- Pages
- 526-532
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2157012588
- Cited by
- 260
- References
- 11
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention. https://app.cochat.ai/papers/10.1093/jnci/95.7.526
- The paper
- Freedman, A. N., Graubard, B. I., Rao, S. R., McCaskill-Stevens, W., Ballard-Barbash, R., & Gail, M. H. (2003). Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/95.7.526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.